Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1498 other investors.
Redeye returns with a follow-up note to Genovis’ Q2’22 report. We see a relatively weak report, although the growth in the Analytics segment (+31%) was a positive element.
Redeye provides its initial take on Genovis’ Q2’22 report, which came in below our expectations. We consider this a rather weak report from Genovis, although we note that the Analytics segment is continuing to grow solidly (+31%).
Genovis has signed a long-term licensing and supply agreement with a US based biotech company for the supply of SmartEnzymes[TM] to be used in the manufacturing of a clinical therapeutic agent. The new customer represents Genovis' second partner in the Bioprocess application area.
Redeye endorses Genovis entering into a service agreement with evitria AG for LC-MS analysis of recombinant antibodies.
Genovis AB and evitria AG today signed a service agreement to offer evitria's customers fast LC-MS characterization of recombinant antibodies using Genovis proprietary enzyme technologies. evitria AG is a world leading service provider for recombinant antibody expression in CHO cells with headquarters in Zürich, Switzerland.
The Annual General Meeting adopted the following resolutions:
The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.
The Board and the Chief Executive Officer were discharged from liability.
The Board shall consist until the next AGM of five ordinary members without deputies.
Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist and Steve Jordan.
Magnus Gustafsson was elected new Board member.
Redeye returns with a follow-up note to Genovis’ Q1’22 report. We are encouraged to see that the company is reporting yet another solid quarter and that the growth remains high, particularly in the Enzyme business.
Redeye regards Genovis’ Q1’22 report as solid and is encouraged to see continuously strong growth in the Enzyme business.